Tenecteplase shows no benefit over standard care for 90-day functional recovery in patients with minor ischemic stroke and disabling deficits.
Imperative Care, Inc. today announced the presentation of late-breaking, real-world data from a multi-center review of ischemic stroke patients treated with ADAPT 2.0, a next-generation approach to A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback